Methods: Urine was collected from 78 bladder-cancer patients during follow-up, from 20 patients with benign urological disease, and from 20 healthy volunteers. RNA was isolated from exfoliated cells in urine by use of an RNA purification kit, and real-time PCR was performed with specific primers for the amplification of CK20, a marker for TCC urothelium.
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Findings: A strong correlation was found between tumour grade and expression of CK20 in urine. All patients with grade III and IV tumours showed positive CK20 expression in the exfoliated cells, with 100% sensitivity. The sensitivity for lower grades was up to 83%. Out of 13 TCC patients, CK20 expression was found in nine patients who were previously diagnosed by biopsy and had a negative biopsy following treatment. These nine patients were followed up for 6 months, and TCC recurred in four patients.
Interpretation: Quantitative detection of CK20 in exfoliated cells of urine is a simple and non-invasive method for monitoring and follow-up of TCC in patients with bladder cancer. However, more information is needed regarding CK20 expression in non-malignant urological diseases to use it as a marker for routine screening. DNA isolation and bisulfite conversion were performed to evaluate promoter methylation of SFRP1 and CDH1 genes using methyl-specific PCR (MSP).
Findings: Using SFRP1 and CDH1 as surrogate markers, 13 of 41 (32%) and 18 of 48 (38%) patients showed induction of promoter hypermethylation after chemotherapy (p = 0.052 and p = 0.012, McNemar test). However, the rate of demethylation of both markers was 10%. To explore the reversibility of chemotherapyinduced promoter hypermethylation, a subset of 12 patients were treated with a combination of epigenetic therapy and chemotherapy. Two of 12 patients (17%) showed hypermethylation and four of 12 (33%) had an increased rate of promoter demethylation. The dynamic status of promoter methylation is not associated with hormone-receptor status, HER2 expression, age, or stage.
Interpretation: Neoadjuvant chemotherapy can induce promoter methylation of tumour suppressor genes in a significant proportion of patients, which may affect long-term clinical outcome. This trend of promoter hypermethylation of tumour-suppressor genes can be reversed using epigenetic therapy. ). Median progression-free survival was 6.5 months (4.7-8.2).
Interpretation The recommended dose of the EOS regimen in patients with previously untreated AGC was epirubicin 50 mg/ m 2 and oxaliplatin 130 mg/m 2 on day 1, and S-1 40 mg/m 2 twice a day on days 1-14 of every 21-day cycle. This regimen seems to have promising preliminary activity. Interpretation: The current data revealed that increased expression of ABIN-1 was correlated with survival in patients with NSCLC, indicating that ABIN-1 is a novel prognostic marker for NSCLC.
Funding for this study: None. of grade III tumours were positive for p53. There were significantly more p53-positive cases seen in grade II-III tumours than in grade I tumours (p = 0.0036). Similarly, stage T2-T4 tumours stained more frequently and stronger than stage T1 tumours (p = 0.021). No significant association between p53 status and post-operative prognosis was observed in the 3 years of followup (p = 2.131). 
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